Despite the fact that China lags behind in terms of the overall level of genetic engineering drugs, the industry has accumulated rich R&D and industrialization experience as well as capital reserves. Thus, with a host of genetic engineering drug patents to become due, Chinese enterprises, such as Walvax, are committed to the industrialization research of monoclonal antibody, long-acting recombinant protein drugs and other generic drugs with high technical barriers. In April this year, Walvax announced to invest in Shanghai Fengmao to develop and produce genetic engineering generic drugs such as rituximab, bevacizumab, adalimumab, panitumumab, denosumab and long-acting EPO.
New market report “China Genetic Engineering Drug Industry Report, 2011-2012”worked out by ResearchInChina delves into a comprehensive discussion of thegenetic engineering drugindustry from a global perspective and focuses on an insightful review of the sector in China.
Key Topics Covered:
Companies profiled in the report include: Shanghai Lansheng Guojian Pharmaceutical Co., Ltd; Biotech Pharmaceutical Co., Ltd; Anhui Anke Biotechnology (Group) Co., Ltd; GeneScience Pharmaceuticals Co., Ltd; Beijing SL Pharmaceutical Co., Ltd; Jiangsu Sihuan Bioengineering Co., Ltd; Shenzhen Neptunus Interlong Bio-Technique Co., Ltd; 3SBio Inc.; and Tonghua Dongbao Pharmaceutical Co., Ltd.
Title: China Genetic Engineering Drug Industry Report, 2011-2012
Published: July, 2012
1 PROFILE OF BIOPHARMACEUTICAL INDUSTRY
1.1 Definition and Classification
1.2 Genetic Engineering Drugs
2 OVERVIEW OF CHINA GENETIC ENGINEERING DRUG INDUSTRY
2.1 Global Market
2.2 Development Status
2.3 Competition Pattern
2.4 Prospects and Dynamics
3 GENETIC ENGINEERING DRUG MARKET SEGMENTS IN CHINA
3.1 Monoclonal Antibody
3.1.1 Status Quo
3.1.2 Competition Pattern
3.1.3 Prospects and Dynamics
3.2 Recombinant Human Erythropoietin
3.2.1 Status Quo
3.2.2 Competition Pattern
3.2.3 Prospects and Dynamics
3.3 Recombinant Human Interferon
3.3.1 Status Quo
3.3.2 Competition Pattern
3.3.3 Prospects and Dynamics
3.4 Recombinant Human Growth Hormone
3.4.1 Status Quo
3.4.2 Competition Pattern
3.4.3 Prospects and Dynamics
More new market reports by ResearchInChina can be found at http://marketpublishers.com/members/researchinchina/info.htmlBusiness Wire
Last updated on: 01/08/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.